Gilead Sciences, Inc. (NASDAQ:GILD) has received a consensus recommendation of “Buy” from the twenty-three research firms that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $80.94.
Several equities research analysts have recently weighed in on the stock. Wells Fargo & Co downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $95.00 to $68.00 in a research note on Monday, February 11th. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, April 9th. UBS Group upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $75.00 to $77.00 in a research note on Wednesday, April 10th. Cantor Fitzgerald reiterated a “buy” rating and set a $87.00 target price on shares of Gilead Sciences in a research note on Thursday. Finally, Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a research note on Friday. They set an “outperform” rating and a $82.00 target price for the company.
In related news, Director Gayle E. Wilson sold 19,068 shares of the stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the completion of the transaction, the director now directly owns 143,567 shares of the company’s stock, valued at $9,630,474.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John Francis Cogan sold 2,700 shares of the stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $62.61, for a total transaction of $169,047.00. Following the transaction, the director now directly owns 57,560 shares of the company’s stock, valued at $3,603,831.60. The disclosure for this sale can be found here. Insiders have sold 44,802 shares of company stock valued at $2,956,422 over the last three months. 0.20% of the stock is currently owned by corporate insiders.
Shares of GILD traded up $0.99 during mid-day trading on Friday, hitting $65.13. 478,099 shares of the company’s stock were exchanged, compared to its average volume of 7,457,994. Gilead Sciences has a fifty-two week low of $60.32 and a fifty-two week high of $79.61. The company has a market capitalization of $80.37 billion, a price-to-earnings ratio of 10.59, a price-to-earnings-growth ratio of 4.15 and a beta of 1.16. The company has a debt-to-equity ratio of 1.19, a quick ratio of 3.30 and a current ratio of 3.38.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing the consensus estimate of $1.70 by ($0.26). Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same quarter last year, the company posted $1.78 EPS. Gilead Sciences’s quarterly revenue was down 2.6% on a year-over-year basis. Equities research analysts forecast that Gilead Sciences will post 6.3 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were issued a dividend of $0.63 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 annualized dividend and a yield of 3.87%. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s dividend payout ratio is currently 40.98%.
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Read More: What is a bull market?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.